study_id: "CX-NSCLC-201"
protocol: "CX-201"
phase: "Phase II"

# Link to parent portfolio registry
portfolio_registry: "../../portfolio_registry.yml"

# Study-specific paths (relative to study root)
paths:
  raw_data: "data/raw"
  sdtm: "data/sdtm"
  adam: "data/adam"
  outputs: "outputs"
  logs: "logs"

# CDISC specifications
cdisc:
  sdtm_version: "1.7"
  adam_version: "1.1"
  controlled_terminology: "2023-12-15"
  
  # Study-specific SDTM domains
  sdtm_domains:
    - DM
    - AE
    - CM
    - VS
    - LB
    - EX
    - RS
  
  # Study-specific ADaM datasets
  adam_datasets:
    - ADSL
    - ADAE
    - ADLB
    - ADVS
    - ADRS

# Analysis populations
populations:
  FAS: "Full Analysis Set"
  SAFETY: "Safety (received â‰¥1 dose)"

# Treatment arms
treatments:
  - arm_code: "A"
    arm_name: "Compound-X 100mg"

# Study-specific validation rules
validation:
  critical_datasets: ["ADSL", "ADAE", "ADRS"]
  qc_method: "independent_review"  # Targeted QC
  
  non_critical_datasets: ["ADLB", "ADVS"]
  qc_method_nc: "spot_check"  # Minimal QC
